Flushes and Sertraline Trial

University of California San Francisco (UCSF)

Status

Completed

Conditions

Menopause-Hot Flashes

Treatments

Drug: Sertraline

Study type

Interventional

Funder types

Other

Identifiers

NCT00283192

FAST

H5287-23467-03

Details and patient eligibility

About

The primary outcome of FAST (a randomized double-blinded, placebo controlled, trial of the effect of sertraline vs. placebo in reducing the incidence and severity of hot flushes in healthy women) is to determine if 6 weeks of treatment with sertraline (50mg daily for 2 weeks, followed by 100mg per day for 4 weeks, if tolerated) results in a greater reduction in hot flush score (frequency * severity) compared to placebo among women with moderate to severe hot flashes. The secondary aim is to determine the effect of treatment with sertraline on quality of life, sleep, sexual function, and mood.

Full description

The primary aim of FAST is to determine if 6 weeks of treatment with sertraline (50 mg daily for 2 weeks, followed by 100 mg per day for 4 weeks, if tolerated) results in greater reduction in hot flush score (frequency x severity), frequency and severity compared to placebo among women with moderate to severe hot flushes.

The Secondary Aims:To determine the effect of treatment with sertraline on quality of life, sleep, sexual function, mood, and cognitive function. To determine if a modified, short version of a sexual function instrument is valid.

Sex

Female

Ages

40 to 60 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Age 40 - 60 years old
Report > 14 hot flushes per week
Willing to be randomized to sertraline or placebo
Sign informed consent

Exclusion criteria

History of bilateral oophorectomy
Breast or ovarian cancer
Liver disease
Kidney disease requiring dialysis
History of major depression (reported history of depression requiring therapy, hospitalization for depression, taking antidepressant drugs, history of suicide attempt)
History of bipolar affective disorder (reported history of bipolar disorder requiring therapy, medications, hospitalized for bipolar disorder)
Seizure disorder
History of hypersensitivity to sertraline or to SSRIs
Pregnancy or breast feeding
Any medical or psychiatric condition which, in the investigator's opinion, would preclude the participant from adhering to the protocol or completing the trial;
No estrogens or progestins for 3 months prior to screening or during enrollment
Selective estrogen receptor modulators (SERMS)
The following medications: clonidine, gabapentin, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, selective serotonin reuptake inhibitors (SSRIs), megesterol , oral contraceptives, androgens; and medications that are listed on the Pfizer Pharmaceutical drug insert as "contraindicated"